

*James Corsetti* 04/01/2011

**CURRICULUM VITAE**

**JAMES P. CORSETTI, M.D., PH.D.**

April 1, 2011

University of Rochester Medical Center  
Dept. of Pathology and Laboratory Medicine  
601 Elmwood Ave., Box 608  
Rochester, N.Y. 14642  
Phone: (585) 275-4907  
Fax: (585) 273-3003

4 Candlewood Circle  
Pittsford, N.Y. 14534  
Phone: (585) 248-3164

URMC Central Laboratories  
77 Ridgeland Road  
Rochester, NY 14623  
Phone: (585) 350-2670  
Fax: (585) 419-6115

e-mail: James\_Corsetti@urmc.rochester.edu

**CITIZENSHIP**

United States of America

**EDUCATION**

1982 M.D., Brown University  
1980 Ph.D., Harvard University (Physical Chemistry)  
1971 M.A., Harvard University (Physical Chemistry)  
1969 B.S., University of Rhode Island (Chemistry)

**POST DOCTORAL TRAINING**

1982 - 86 University of Rochester Medical Center, Resident in Pathology  
1985 - 86 University of Rochester Medical Center, Chief Resident in Pathology

**MILITARY EXPERIENCE**

1969 - 75 Rhode Island Army National Guard (Active duty Jan. 1969 to June 1969;  
Fort Jackson SC and Fort Gordon, GA)

## **LICENSURE AND CERTIFICATION**

1983           Diplomat, National Board of Medical Examiners  
1983           State of New York - License 155702  
1987           Certification, American Board of Pathology, Anatomic and Clinical Pathology  
1998           Recertification, American Board of Pathology, Anatomic and Clinical Pathology  
2008           Fellow of the Academy of Clinical Biochemistry

## **FACULTY APPOINTMENTS**

1986 - 1992   Assistant Professor of Pathology and Laboratory Medicine  
                  University of Rochester School of Medicine and Dentistry, Rochester, NY 14642  
1992 - 2010   Associate Professor of Pathology and Laboratory Medicine  
                  University of Rochester School of Medicine and Dentistry, Rochester, NY  
2010 -        Professor of Pathology and Laboratory Medicine  
                  University of Rochester School of Medicine and Dentistry, Rochester, NY

## **PROFESSIONAL HOSPITAL AND ADMINISTRATIVE APPOINTMENTS**

1986 -        Attending Pathologist, Strong Memorial Hospital  
1986 - 1997   Director of General Clinical Chemistry Laboratory, Strong Memorial Hospital  
1986 - 1997   Assistant Director of Clinical Chemistry Unit, Strong Memorial Hospital  
1988 - 1997   Director of STAT Laboratory, Monroe Community Hospital  
1996 - 1997   Assistant Director of Clinical Hematology Laboratory, Strong Memorial Hospital  
1996 - 1998   Acting Director, Flow Cytometry Laboratory, Strong Memorial Hospital  
1997 - 1997   Director of Laboratories, Wyoming County Community Hospital  
1998 - 1999   Director of Cell Marker (Flow Cytometry) Laboratory, Strong Memorial Hospital  
1998 - 1999   Assistant Director of Laboratories, Wyoming County Community Hospital  
1998 - 2006   Director of Automated Laboratory, Strong Memorial Hospital  
1999 -        Director of Specimen Management Section, Strong Memorial Hospital  
2006 -        Associate Director of Automated Laboratory, Strong Memorial Hospital  
2006 -        Associate Director of Protein Laboratory, Strong Memorial Hospital  
2009 -        Director of Laboratories, University of Rochester Medical Center Clinical Trials  
                  Central Laboratory

My clinical service responsibilities are and have been extensive and wide-ranging. I am flexible, adaptable, and a quick study. This has enabled me to be a uniquely valuable resource to the Department. I have functioned in multiple areas at many different times, and more than once, when immediate coverage of a particular clinical service was crucial, my expertise was enlisted. My versatility is apparent from my current major clinical appointments: 1. Director of Laboratories of the URM Clinical Trials Central Laboratory, 2. Associate Director of the Automated Laboratory (Hematology), 3. Associate Director of the Protein Laboratory, and 4. Medical Director of the Specimen Management Section.

As Director of Laboratories of the Clinical Trials Central Laboratory, I hold the New York State license under which all testing in the Laboratory is performed. At present this includes the areas of Chemistry, Diagnostic Immunology, Serology, Endocrinology, Hematology, Coagulation, HIV testing, and Urinalysis. The Laboratory is a for-profit endeavor and major initiative of the URMC Dept. of Pathology and Laboratory Medicine to provide clinical laboratory services primarily to the biotech and pharmaceutical industries as well as the academic community. It is a separate organization from the URMC Clinical Laboratories, and as such, it has independent governance under my license as Director of Laboratories. In the near future my responsibilities will expand dramatically as the Laboratory is slated to become the primary location for the performance of URMC outpatient clinical laboratory testing. Outpatient testing is a major program of the Dept. to provide clinical laboratory services to surrounding healthcare providers outside the URMC sphere. It is a significant effort as it currently makes up approximately 60% of the Automated Laboratory workload.

As Associate Director of the Automated Laboratory, I am responsible for overseeing multiple high-volume areas including automated blood cell counting (CBC/differentials), manual differential counting, cell analysis of body fluids, and macroscopic and microscopic urinalysis. All of these areas are vital for the short and long term management of patients. This requires significant effort on my part in terms of responsibilities related to setting lab policy, instrumentation, quality control and assurance, consultation with the technical and clinical staff, training, and personnel management. I also am responsible for interpretive reporting of glucose tolerance testing results on a daily basis.

As Associate Director of the Protein Laboratory, I share sign-out responsibilities (50%) for interpretation of third-party-reimbursable protein electrophoresis testing in addition to administrative duties in the laboratory. Our protein electrophoresis testing is high volume for a largely manual test, and it requires interpretive reporting of results by a pathologist. Typically, the Protein Laboratory receives about 60 cases per day with each case requiring significant time and effort for interpretation.

As Medical Director of the Specimen Management Section, I am responsible for setting policy related to issues regarding specimen handling including assessment of appropriateness for analysis, sample preparation for analysis, work flow optimization, and administration of the section (approximately 80 FTE's) that receives on the order of 6,000 tubes of blood per day as well as other specimens for distribution to the various laboratories in the Department.

In my years on the faculty of the URMC Dept. of Pathology and Laboratory Medicine, I have worn many hats and I have made many significant contributions to the clinical missions of the Department. Although, I have major expertise in Clinical Chemistry deriving not only from residency training but also from my pre-medical school training as a PhD in Physical Chemistry; I have been put in the breach multiple times in a variety of roles to assure continued delivery of laboratory services at the highest level. These range from my Directorships under contractual arrangements of the Department to provide laboratory services involving primarily a geriatrics hospital (Monroe Community Hospital) and a community hospital (Wyoming County Community Hospital) to Hematopathology, a specialized area, when the need arose for coverage. Not long after, duties expanded to include Directorship of the Flow Cytometry Laboratory, a position requiring highly-specialized expertise in the area of cell markers in hematopoietic malignancies. In each of these cases, my abilities to quickly take on such disparate sets of tasks have made me a valuable resource in terms of assuring the departmental mission. In spite of these significant past and present commitments to clinical service, I have managed to make significant contributions to the teaching programs of the Department and medical school and to cultivate a research program that now has the potential to make more significant contributions in terms of basic and translational research results in the area of cardiovascular disease including the possibility of IP applications.

## **PROFESSIONAL MEMBERSHIPS**

Academy of Clinical Laboratory Physicians and Scientists  
American Association for Clinical Chemistry  
American Chemical Society  
American Diabetes Association  
American Heart Association, Arteriosclerosis Council  
International Atherosclerosis Society

## **PROFESSIONAL ADMINISTRATIVE ASSIGNMENTS**

1988 - 1997 Chair, Blood Utilization Committee, MCH  
1990 - 1997 Member, Medical Advisory Council, MCH  
1990 - 2001 Member, Committee on Fellowship and Pilot Projects of the University of Rochester Cancer Center  
1991 - 1998 Member, Residency Review Committee, Dept. of Pathology and Laboratory Medicine, University of Rochester Medical Center  
1992 - 1998 Editor, Clinical Pathology Newsletter  
1995 - Member, Rochester Institute of Technology Institutional Review Board for the Protection of Human Subjects in Research  
1998 - Member, Council of the Medical Staff, University of Rochester Medical Center  
2004 - Member, Strong Memorial Hospital Credentials & Privilege Review Committee  
2008- Member, Corporate Medical Policy Committee (Blue Cross Blue Shield Central NY Region)

## **HONORS**

1977 Sigma Xi Science Research Society  
2000 Who's Who in Science and Engineering  
2009 America's Top Pathologists.  
2010 Who's Who in America.

## TEACHING EXPERIENCE

**Harvard University (1969 - 1975):** As a Ph.D. candidate in physical chemistry, I served extensively as a Teaching Assistant in inorganic and physical chemistry courses (1969 - 1975).

**Wesleyan University (1977):** I was director of the first year laboratory course in inorganic chemistry for a class of approximately 300 students that included delivering regular formal lectures.

**University of Rochester Department of Pathology and Laboratory Medicine (1982 - 1996):** As a Resident, Chief Resident, and faculty, I participated extensively in the teaching of Pathology to first and second year medical students.

**University of Rochester Department of Pathology and Laboratory Medicine, Pathology 601 Course (1987 - 2000):** I participated in a fourth year medical student elective in Laboratory Medicine in which I gave lectures in Clinical Chemistry and in 1999 and 2000, I served as Course Director.

**University of Rochester Department of Pathology and Laboratory Medicine, Pathology Residency Program (1996 - 1999) - Clinical Hematology:** I have had major resident teaching responsibilities in laboratory Hematology including methods of instrumental, microscopic and flow cytometric analyses. This activity was performed in the context of daily clinical service hematology sign-out responsibilities (I was on-service 50% of the time) at which point I did one-on-one resident teaching using clinical material as a basis.

**University of Rochester Department of Pathology and Laboratory Medicine, Pathology Residency Program (1986 - present) - Clinical Chemistry:** I have had major teaching responsibilities in Clinical Chemistry both in required and elective rotations. The initial rotation is required for certification in Clinical Pathology and is given approximately 4 - 6 times per year. My responsibilities focus on the modern automated clinical laboratory in which I spend, minimally 15 hours per rotation presenting in the form of lectures and case studies a wide range of important issues in this area (Laboratory Automation, Methods of Laboratory Quantitation, Blood Gas Measurement, Acid-Base Balance, Laboratory Quality Control, Laboratory Validation Procedures, Receiver-Operator Characteristic Analysis, Pancreatitis, Clinical Laboratory Planning).

**University of Rochester Department of Pathology and Laboratory Medicine, Year Two Case Seminars in Laboratory Medicine (2000 - present):** My current major involvement with medical student teaching centers on directing a required course in Laboratory Medicine for second year medical students as part of the sequence of blocks in the Second Year Case Seminars series. I designed the course at its inception and I have served as its Director ever since. The course consists of a multi-faculty approach to major areas of Laboratory Medicine including Blood Banking, Chemical Pathology, Hematology, Microbiology, and Molecular Diagnostics. The course includes 10 hours of lectures and 10 hours of laboratories in these areas. In addition to the planning, administration, and student evaluation, I am also responsible for 8 contact hours in the Clinical Chemistry laboratory of the course. I have chosen to focus in the last several years on the topic of liver function testing based on student feedback in terms of a perceived lack of coverage in other areas of the curriculum regarding this important subject.

## PEER REVIEW

### CARDIOVASCULAR DISEASE (LAST FIVE YEARS)

Circulation (7)  
Arteriosclerosis, Thrombosis, and Vascular Biology (2)  
American Journal of Cardiology (6)  
Atherosclerosis (3)  
Cardiology Journal (2)  
Cardiovascular Therapeutics (1)

### OTHERS

American Journal of Physiology  
Clinical Chemistry  
Metabolism: Clinical and Experimental  
Vascular Health and Risk Management

## PRESENTATIONS

### ABSTRACTS

- May, 1992 "Cell Heterogeneity in the Uptake of LDL and Apo B Expression in Primary Rat Hepatocytes". **JP Corsetti**, JD Sparks, and CE Sparks. (Poster Presentation) XI International Symposium on Drugs Affecting Lipid Metabolism, Palazzo dei Congressi - Palazzo Affari, Florence, Italy.
- April, 1993 "Particle-Stabilized Epitopes for Apolipoprotein Immunoassay Standardization". **JP Corsetti**, JD Sparks, MR Violante, and CE Sparks. (Poster Presentation) International Conference, HDL-Cholesterol and Triglycerides: Role in Coronary Heart Disease and Laboratory Measurement, Washington, DC.
- Oct., 1994 "Subpopulations of Streptozotocin-Induced Diabetic Rats by Multivariate Statistical Analysis of Insulin, Glucose, and Lipoprotein Concentrations". **JP Corsetti**, CE Sparks, and JD Sparks. (Poster Presentation) Xth International Symposium on Atherosclerosis (Diabetes, Obesity, and Atherosclerosis Satellite Symposium), Toronto, Canada.
- Sept., 1995 "Pseudoparaproteinemia Due to Hemoglobinopathy". R Lazova, J Sterry, and **JP Corsetti**. (Poster Presentation) American Society of Clinical Pathology/College of American Pathologists - National Meeting, New Orleans, LA.
- Nov., 1995 "The Hepatic Pathway for Insulin-Mediated Intracellular Degradation of Apo B is Resistant to Insulin in Hyperinsulinemic Zucker Diabetic Fatty Rats". JD Sparks, TL Phung, R Khurana, **JP Corsetti**, and CE Sparks. (Poster Presentation) XII International Symposium on Drugs Affecting Lipid Metabolism, Houston, TX.

- July, 1996 "Characterization and Role of Insulin in the Hyperlipidemia of the Male Zucker Diabetic Fatty Rat", **James P. Corsetti**, Janet D. Sparks, Richard G. Peterson, Robert L. Smith and Charles E. Sparks. (Poster Presentation) 48'th Annual Meeting - American Association for Clinical Chemistry, Chicago, IL).
- June, 2000 "Glucose-stimulated Insulin Secretion Suppresses Hepatic Triglyceride-rich Lipoprotein and Apo B Production *In Vivo*". Doru V. Chirieac, Lucian R. Chirieac, **James P. Corsetti**, Joanne Cianci, Charles E. Sparks, Janet D. Sparks. (Poster Presentation) American Diabetes Association Meeting, San Antonio, TX published in Diabetes. 2000;49(Supplement 1):A281.
- May, 2004 "Apolipoprotein B Determines Overall Risk and Lp(a) Subgroup Risk for Recurrent Coronary Events in Postinfarction Patients with Metabolic Syndrome". **James P. Corsetti**, Wojciech Zareba, Arthur J Moss, Charles E Sparks. (Poster Presentation) 5'th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, San Francisco, CA published in Arteriosclerosis, Thrombosis and Vascular Biology. 2004;24:E16.
- July, 2005 "Elevated HDL Determines Risk of Recurrent Coronary Events within a High-Risk Subgroup of Non-Diabetic Postinfarction Patients with Hypercholesterolemia and Inflammation". **James P. Corsetti**, Wojciech Zareba, Arthur J. Moss, David L. Rainwater, and Charles E. Sparks. (Poster Presentation) 2'nd International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and the Metabolic Syndrome. New York, NY.
- Oct., 2007 "Plasminogen Activator Inhibitor-1 Promoter Polymorphism (4G/5G) Predicts Risk of Recurrent Coronary Events in Non-Hypercholesterolemic, Non-Hypertriglyceridemic Postinfarction Patients". **James P. Corsetti**, Dan Ryan, Arthur J. Moss, Wojciech Zareba, and Charles E. Sparks. (Poster Presentation) XVI Drugs Affecting Lipid Metabolism Symposium. New York, NY published in Journal of Clinical Lipidology. 2007;1:447.
- Oct., 2008 "The Effects of Anti-A and Anti-B on Platelet Function: An in vitro Model of ABO Non-Identical Transfusion". M. Refai, E. Masel, K Gettings, R Phipps, S Spinelli, **J Corsetti**, L Fialkow, C Francis, N Blumberg. 61'st AABB Annual Meeting. Montreal, Canada.

## RESEARCH PRESENTATIONS

- Oct., 2005 The Role of Metabolic Syndrome in Postinfarction Patients. Grand Rounds, Dept. of Pathology and Laboratory Medicine, University of Rochester Medical Center.
- June, 2007 Outcome Event Mapping and Cardiovascular Disease. Metabolic Research Group, Dept. of Pathology and Laboratory Medicine. University of Rochester Medical Center.

- Jan, 2008 Identification of High- and Low-Risk Patient Subgroups by Outcome Event Mapping. Metabolic Research Group, Dept. of Pathology and Laboratory Medicine. University of Rochester Medical Center.
- Oct, 2010 Invited Speaker - Symposium on Lipids and HDL, University of Groningen and University Medical Center; Groningen, The Netherlands. The Role of Impaired HDL Remodeling in the Establishment of Risk for Primary and Secondary Coronary Events.

### **TECHNOLOGY PRESENTATIONS**

- Oct., 1995 Session Chairperson, Automation and the Clinical Laboratory, Upstate NY Section American Association for Clinical Chemistry Regional Meeting, Niagara-on-the-Lake, Canada.
- March, 2006 Identification of High-Risk Patient Subgroups. Ortho-Clinical Diagnostics, Inc., Rochester, NY.
- Dec., 2006 Identification of High-Risk Patient Subgroups by Outcome Event Mapping. Unipath. Diagnostics Co., Rochester, NY.

## ORIGINAL PUBLICATIONS

**Corsetti JP**, and Kohler BE. Ground and Excited-State Dipole Moments of all-trans retinal and all-trans-retinylidene-n-butylamine in solution. *Journal Chemical Physics*. 1977;67:5237 - 5243.

**Corsetti JP**. Solvent Shift Theory and the Photochemistry of 2,4-Hexadienal. Ph.D. Dissertation - Physical Chemistry. Harvard University 1979.

**Corsetti JP**, Cox MT, Cox C, Blumberg N, Leary J, and Doherty R. A Comparison of Quantitative Acid Elution Technique and Flow Cytometry for Detecting Low Levels of Fetomaternal Hemorrhage. *Annals Clinical Laboratory Science*. 1987;17:197 - 206.

Szilagyi PG, **Corsetti JP**, Callahan CM, McCormick K, and Metlay LA. A Patient with Clinical Features of Leprechaunism and Abnormal Pancreatic Exocrine Hypoplasia. *Pediatric Pathology*. 1987;7:51- 61.

**Corsetti JP**, Cowles J, Cox MT, and Blumberg N. A Rapid and Accurate Single-Drop Modification of the Acid-Elution Technique for Detecting Fetomaternal Hemorrhage. *Vox Sanguinis*. 1988;54:39 - 42.

**Corsetti JP**, Sotirchos S, Cox C, Cowles J, Leary J, and Blumberg N. The Correction of Cellular Autofluorescence in Flow Cytometry by Mathematical Modeling of Cellular Fluorescence. *Cytometry*. 1988;9:539 - 547.

**Corsetti JP**, Weidner CH, Cianci J, and Sparks CE. The Labeling of Lipoproteins for Studies of Cellular Binding with a Fluorescent Lipophilic Dye. *Analytical Biochemistry*. 1991;195:122 - 128.

**Corsetti JP**, Sterry J, Sparks CE, Sparks JD, and Weintraub M. The Effect of Weight Loss on Serum Lipoprotein(a) Levels in an Obese Population. *Clinical Chemistry*. 1991;37:1191 - 1195.

**Corsetti JP**, Way BA, Sparks CE, and Sparks JD. Immunolocalization, Quantitation and Cellular Heterogeneity of Apolipoprotein B in Rat Hepatocytes. *Hepatology*. 1992;15:1117 - 1124.

**Corsetti JP**, Sparks JD, and Sparks CE. Cellular Heterogeneity in Binding and Uptake of LDL in Primary Rat Hepatocytes. *Hepatology*. 1993;17:645 - 650.

**Corsetti JP**, Cox C, Schulz TJ, and Arvan DA. The Use of Combined Serum Amylase and Lipase for Suspected Acute Pancreatitis. *Clinical Chemistry*. 1993;39:2495 - 2499.

Sparks JD, **Corsetti JP**, and Sparks CE. Liver Regrowth and Apolipoprotein B Secretion by Rat Hepatocytes Following Partial Hepatectomy. *Metabolism*. 1994;43:681 - 690.

Lazova RZ, Sterry JA, and **Corsetti JP**. Pseudoparaproteinemia Due to Hemoglobinopathy. *Clinical Chemistry*. 1995;41:1321 - 1322.

Sparks JD, Phung TL, Bolognino M, Cianci J, Khurana R, Peterson RG, Sowden MP, **Corsetti JP**, and Sparks CE. Lipoprotein Alterations in 10 and 20 Week Old Zucker Diabetic Fatty Rats: Hyperinsulinemic Versus Insulinopenic Hyperglycemia. *Metabolism*. 1998;47:1315 - 1324.

**Corsetti JP**, Sparks JD, Peterson RG, Smith RL, and Sparks CE. Effect of Dietary Fat on the Development of Non-Insulin Dependent Diabetes Mellitus in Obese Zucker Diabetic Fatty Male and Female Rats. *Atherosclerosis*. 2000;148:131 - 141.

Sparks JD, Shaw WN, **Corsetti JP**, Bolognino M, Pesek JF, and Sparks CE. Insulin-Treated Zucker Diabetic Fatty Rats Retain the Hypertriglyceridemia Associated with Obesity. *Metabolism*. 2000;49:1424 - 1430.

Chirieac DV, Chirieac LR, **Corsetti JP**, Cianci J, Sparks CE, and Sparks JD. Glucose-Stimulated Insulin Secretion Suppresses Hepatic Triglyceride-Rich Lipoprotein and Apo B Production. *Am Jour Physiol Endocrinol Metab*. 2000;279:E1003 - E1011.

**Corsetti JP**, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, and Sparks CE. Metabolic Syndrome Best Defines the Multivariate Distribution of Blood Variables in Postinfarction Patients. *Atherosclerosis*. 2003;171:351 - 358.

**Corsetti JP**, Zareba W, Moss AJ, and Sparks CE. Apolipoprotein B Determines Risk for Recurrent Coronary Events in Postinfarction Patients with Metabolic Syndrome. *Atherosclerosis*. 2004;177:367 - 373.

**Corsetti JP**, Zareba W, Moss AJ, and Sparks CE. Serum Glucose and Triglyceride Determine High-Risk Subgroups in Non-Diabetic Postinfarction Patients. *Atherosclerosis*. 2005;183:293 - 300.

**Corsetti JP**, Zareba W, Moss AJ, Rainwater DL, and Sparks CE. Elevated HDL Is a Risk Factor for Recurrent Coronary Events in a Subgroup of Non-Diabetic Postinfarction Patients with Hypercholesterolemia and Inflammation. *Atherosclerosis*. 2006;187:191 - 197.

**Corsetti JP**, Rainwater DL, Moss AJ, Zareba W, and Sparks CE. High Lipoprotein-Associated Phospholipase A<sub>2</sub> Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients. *Clinical Chemistry*. 2006;52:1331 - 1338.

Multiple co-authors including **Corsetti JP**. Collaborative Meta-Analysis of Individual Participant Data from Observational Studies of Lp-PLA<sub>2</sub> and Cardiovascular Diseases. *European Journal of Cardiovascular Prevention and Rehabilitation*. 2007;14:3 - 11.

**Corsetti JP**, Ryan D, Moss AJ, Rainwater DL, Zareba W, and Sparks CE. Glycoprotein Iba Polymorphism (T145M), Elevated Lipoprotein-Associated Phospholipase A<sub>2</sub>, and Hypertriglyceridemia Predict risk for Recurrent Coronary Events in Diabetic Postinfarction Patients. *Diabetes*. 2007;56:1429 - 1435.

Ryan TP, Sloand JA, Winters PC, **Corsetti JP**, Fisher SG. Chronic Kidney Disease Prevalence and Rate of Diagnosis. *American Journal of Medicine*. 2007;120:981 - 986.

Goldenberg I, Moss AJ, Block R, Ryan D, **Corsetti JP**, McNitt S, Eberly SW, Zareba W. Polymorphism in the Cholesteryl Ester Transfer Protein Gene and the Risk of Early Onset Myocardial Infarction among Cigarette Smokers. *Annals of Noninvasive Electrocardiology*. 2007;12:364 - 374.

**Corsetti JP**, Ryan D, Moss AJ, Zareba W, and Sparks CE. NAD(P)H Oxidase Polymorphism (C242T) and High HDL Cholesterol Associate with Recurrent Coronary Events in Post infarction Patients. *Atherosclerosis*. 2008;196:461-468.

**Corsetti JP**, Ryan D, Moss AJ, Rainwater DL, Zareba W, and Sparks CE. Plasminogen Activator Inhibitor-1 Polymorphism (4G/5G) Predicts Recurrence in Non-Hyperlipidemic Postinfarction Patients. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2008;28:548-554.

**Corsetti JP**, Ryan D, Rainwater DL, Moss AJ, Zareba W, Block RC, and Sparks CE. Lp(a) and Risk of Recurrent Cardiac Events in Obese Postinfarction Patients. *Obesity*. 2008;16:2717-2722.

Block R, **Corsetti JP**, Goldenberg I, Vorobiof G, McNitt S, Ryan D, Zareba W, Moss AJ. The Common Apolipoprotein A-1 Polymorphism -75A>G is Associated with Ethnic Differences in Recurrent Coronary Events after Recovery from an Acute Myocardial Infarction. *Heart International*. 2009;4:e8.

Multiple co-authors including **Corsetti JP**. Lipoprotein-Associated Phospholipase A<sub>2</sub> and Risk of Coronary Disease, Stroke, and Mortality: Collaborative analysis of 32 Prospective Studies. *Lancet*. 2010;375:1536-1544.

**Corsetti JP**, Gansevoort RT, Sparks CE, Dullaart RPF. HDL Protection against Primary Cardiac Risk is Lost with Inflammation. *European Journal of Clinical Investigation*. 2010;40:483-489.

Casas JP, Ninio E, Panayiotou A, Palmén J, Cooper JA, Ricketts SL, Nicolaidis AN, **Corsetti JP**, et al. *PLA2G* Genotype, Lp-PLA<sub>2</sub> Activity and Coronary Heart Disease Risk in 8506 Cases and 12,620 Controls of European Ancestry. *Circulation*. 2010;121:2284-2293.

**Corsetti JP**, Ryan D, Rainwater DL, Moss AJ, Zareba W, and Sparks CE. Decreased CETP Activity Associates with Recurrent Risk in Postinfarction Patients with High HDL Cholesterol and High CRP. *Atherosclerosis, Thrombosis, and Vascular Biology*. 2010;30:1657-1664.

**Corsetti JP**, Gansevoort RT, Navis GJ, Sparks CE, Dullaart RPF. *LPL* Polymorphism (D9N) Predicts Cardiovascular Disease Risk Directly and Through Interaction with *CETP* Polymorphism (TaqIB) in Women with High HDL Cholesterol and CRP. *Atherosclerosis*. 2011;214:373-376.

Refaai MA, Fialkow LB, Heal JM, Henrichs KF, Spinelli SL, Phipps RP, Masel E, Smith BH **Corsetti JP**, Francis CW, Bankey PE, Blumberg N. An Association of ABO Non-Identical Platelet and Cryoprecipitate Transfusions with Altered Red Cell Transfusion Needs in Surgical Patients. *Vox Sanguinis*. 2011, In Press (DOI: 10.1111/j.1423-0410.2010.01464.x)

## **BOOK CHAPTERS**

**Corsetti JP**, and Arvan DA. Acute Pancreatitis. In "Diagnostic Strategies for Common Medical Problems". Black ER, Bordley DR, Tape TG, and Panzer RJ, eds., ACP, Philadelphia, 1999.

**Corsetti JP**, and Arvan DA. Acute Viral Hepatitis. In "Diagnostic Strategies for Common Medical Problems". Black ER, Bordley DR, Tape TG, and Panzer RJ, eds., ACP, Philadelphia, 1999.

**Corsetti JP**, and Arvan DA. Hypercalcemia. In "Diagnostic Strategies for Common Medical Problems". Black ER, Bordley DR, Tape TG, and Panzer RJ, eds., ACP, Philadelphia, 1999.

**Corsetti JP**, and Arvan DA. Obstructive Jaundice. In "Diagnostic Strategies for Common Medical Problems". Black ER, Bordley DR, Tape TG, and Panzer RJ, eds., ACP, Philadelphia, 1999.

### **OTHER PUBLICATIONS**

**Corsetti JP**. Book Review of *Geriatric Clinical Chemistry Reference Values*, eds: Faulkner WR and Meites S. American Association for Clinical Chemistry Press, Washington, DC, 1994. J Am Geriatrics Soc 42:1135(1994).

“Journal Club” presentation of [**Corsetti JP**, Rainwater DL, Moss AJ, Zareba W, and Sparks CE. High Lipoprotein-Associated Phospholipase A<sub>2</sub> Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients. Clinical Chemistry. 2006;52:1331 - 1338] in Clinical Laboratory. 2007;53:113.

### **PATENTS**

2007 US Patent Application No. 11/809,832: IDENTIFYING RISK OF A MEDICAL EVENT. Inventors: **James P. Corsetti**, Charles E. Sparks, Daniel H. Ryan, Arthur J. Moss.

### **CONSULTATION**

Consultant, Ortho Clinical Diagnostics (Division of Johnson&Johnson), Metabolic Disease Testing

### **RESEARCH GRANTS**

### **COMPLETED AWARDS**

1986 - 87 PHS S7RR05403(BRSG Sub), Zonal Heterogeneity of Hepatic Lipoprotein Metabolism by Flow Cytometry, **PI - JP Corsetti**, \$7,141.

1987 - 88 NYS Health Research Council D4-031, Heterogeneity of Hepatic Lipoprotein Metabolism in Streptozotocin-Induced Diabetic Rats, **PI - JP Corsetti**, \$20,000.

- 1988 Marion Laboratories, Diltiazem and Intracellular Calcium Mediation of Lipoprotein Metabolism, **Co-PI - JP Corsetti**, PI - Charles E. Sparks, \$53,872.
- 1988 - 91 American Heart Association Grant-in-Aid 880793, Lipoprotein Regulation by Insulin and Free Cytosolic Calcium, **PI - JP Corsetti**, \$99,000.
- 1998 University of Rochester Medical Center, Dept. of Pathology and Laboratory Medicine Faculty Development Program, Hepatocellular Heterogeneity of Lipoprotein Metabolism, **PI - JP Corsetti**, \$5,000.
- 2009 Ortho-Clinical Diagnostics, Inc. Blood Samples Collection from Human Subjects for Metabolic Disease Study. **PI - James P. Corsetti**. \$400,000./year.

### **FUTURE RESEARCH**

Beginning in 2003 as reported in a series of nine first-authored publications, we have investigated recurrent cardiovascular disease (CVD) risk in post-MI patients in terms of blood biomarkers and SNP's representative of metabolic, inflammatory/oxidative stress, and thrombogenic processes. The overarching idea driving this work was based on concepts from personalized medicine suggesting that different blood and genetic biomarkers would be specific in predicting risk in a given patient. However, limitations in current state-of-the-art approaches prevent identification of such markers. As a transitional phase, we hypothesized that personalized medicine tenets may be approached by recognizing patient subgroups with common pathophysiologic features for whom sets of biomarkers would be effective. Based on these ideas, we developed an approach for recognition of such patient subgroups that we call "outcome event mapping" (OEM). OEM is a graphical exploratory data analysis tool that maps risk over a bivariate risk domain of two biomarkers. With it, we have identified several high-risk subgroups in post-MI patients. One of these is particularly worthy of note as it occurs in patients with high levels of HDL cholesterol and C-reactive protein. This finding is surprising as high levels of HDL cholesterol (the "good" cholesterol) have for decades been considered anti-atherogenic and thus protective against CVD risk. However, there is accumulating evidence that HDL becomes dysfunctional and actually pro-atherogenic under conditions of low-grade systemic inflammation. We believe this notion underlies our observation of high HDL-associated risk.

Recently, we identified a similar subgroup of subjects from a generally healthy population from the Netherlands with no history of CVD. Thus, the high-risk high HDL/high CRP subgroup appears to be present in both primary and recurrent CVD, and as such it becomes an important patient subgroup for further study as many therapeutic approaches aimed at further reducing CVD risk beyond treatment with statins involves various means of raising HDL levels. Already such attempts have proved flawed (torcetrapib) in that several have been terminated in light of findings of actually increased CVD risk with such approaches.

Thus, our plans are: first, to investigate and probe pathophysiologic mechanisms involved in risk establishment in such patients by epidemiologic studies using blood and genetic biomarkers with our OEM approach and advanced statistical analyses related to elucidating relationships among

pathophysiologic mechanisms (eg., Bayesian network analysis); and second, to perform proteomic and lipidomic analyses of normal and altered HDL particles to work-out physico-chemical changes related to inflammation-induced dysfunctional transformation. To this end, we have in 2009 begun the first phase of the work by submitting two grant proposals for population/biomarker studies (American Heart Association. Founders Affiliate Grant-in-Aid Program. "Elevated HDL Cholesterol and Cardiovascular Disease Risk". PI - James P. Corsetti; and NIH. Challenge Grants in Health and Science Research. "Mechanisms of High HDL-C Associated Cardiovascular Risk Using Bayesian Networks". PI - James P. Corsetti). Proposal reviews indicated that the work would be significantly strengthened by inclusion of laboratory analyses to characterize altered HDL. We will follow this strategy of including both phases in an NIH proposal especially as related to state-of-the-art proteomic and lipidomic analyses of HDL subclasses. Furthermore, we have the ability to develop both national and international collaborations related to population studies that will lend further support for the work in providing access to appropriate study subjects and patients.